# Ravulizumab Outcomes in Polish Patients With aHUS

> **NCT07399730** · — · NOT_YET_RECRUITING · sponsor: **AstraZeneca** · enrollment: 80 (estimated)

## Conditions studied

- Atypical Hemolytic Uremic Syndrome

## Interventions

- **DRUG:** Ravulizumab

## Key facts

- **NCT ID:** NCT07399730
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2030-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07399730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07399730, "Ravulizumab Outcomes in Polish Patients With aHUS". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07399730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*